The use of circulating tumour DNA to screen for cancer in asymptomatic individuals is the goal of Grail, initially set up by Illumina. This company is now raising a large amount of capital to develop this project on a much ...

In clinical oncology, obtaining sequence data from tumour samples has become practical in terms of logistics, turnover time and costs. The major issue now is the interpretation of this sequence to define actionable targets, ...